Compare Emerson Electric Co. (EMR) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Cassava Sciences Inc — how do they compare? Emerson Electric Co. trades at $159.06 (market cap $88.72B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Emerson Electric Co. is far larger — about 2251.8× Cassava Sciences Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Cassava Sciences Inc for 37 Days on average.
| EMR | FLNA | |
|---|---|---|
Market Cap | $88.72B | $39.40M |
Volume | 2,355,255 | 759,018 |
Sector | Industrials | Health |
52-Week High | $164.38 | $4.64 |
52-Week Low | $123.30 | $0.68 |
Typical Hold Time | 81 Days | 37 Days |
Enterprise Value | $99.80B | -$43.28M |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected at $18.6B for 2026, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. The stock faces resistance near $160, with support at $158.
Outlook remains positive given earnings momentum and a consensus price target of $165.90, implying ~4% upside. Risks include debt levels rising to 31.26% of assets in 2025 and macroeconomic pressures on industrial demand. Institutional sentiment is bullish, with 53% of analysts rating Buy.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
